33 results
Thumbnail

D1.414 - The Clinical Course in a normal C1-Inhibitor Hereditary Angioedema family with Factor XII mutation

Thumbnail

D1.416 - Regulatory T Cells Induced by B cells Decreased Osteoclast Activity and Alleviated Disease Severity of Collagen Antibody Induced Arthritis

Thumbnail

D1.418 - An EBP Gene Variant in a Child with Immunodeficiency: A Case from the Chondrodysplasia Pontata Spectrum

Thumbnail

D1.419 - The management of Immunological Diseases in Internal Medicine Departments

Thumbnail

D1.420 - Lymphoma in CVID: on the edge between immune dysregulation and malignancy

Thumbnail

D1.404 - Live Renal Transplantation Outcome in Egyptian Cohort: A Single Center Study

Thumbnail

D1.405 - Establishment of a Mouse Nasal Epithelial Cell Air–Liquid Interface Culture System and Its Application in Mucosal Barrier Research

Thumbnail

D1.407 - Real-world patient characterization, prior long-term prophylactic prescribing patterns, and treatment outcomes for adults on berotralstat with hereditary angioedema in Japan

Thumbnail

D1.409 - Regulation of the intestinal epithelial barrier by the endocannabinoid system

Thumbnail

D1.413 - A Novel Variant of CORO1A Gene Contributing to The Development of Primary Immunodeficiency in Children

Thumbnail

D1.415 - Regulatory T‑Cell Deficiency and NF‑κB/IL‑1β Activation in Dilated Cardiomyopathy

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort